Pharmacological Study

Evidence for safety of Ayurvedic herbal, herbo-metallic and Bhasma preparations on neurobehavioral activity and oxidative stress in rats

Gajendra Kumar, Yogendra Kumar Gupta

PhD Scholar, 1Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India

Abstract

Heavy metals in Ayurvedic formulations have been used for centuries with claimed efficacy and safety. However, concerns are often raised about the toxicity due to heavy metals used in Ayurvedic formulations. The aim of present study is to explore the effect of Calcury tablet, Energic-31 capsule and Basanta Kusumakara Rasa (BKR) on neurobehavioral activity and oxidative stress in rats. Male wistar rats weighing 200-250 g were used and divided into normal control, positive control (mercury chloride, lead acetate, cadmium chloride, sodium arsenite, each 10 mg/kg, p.o for 28 days) and treated group (Calcury tablets at doses of 130, 650, 1300 mg/kg, Energic-31 capsule at doses of 150, 750, 1500 mg/kg and BKR at doses of 26, 130, 260 mg/kg, p.o. for 28 days). After performing the behavioural parameters on the 29th day, homogenate of rat’s brain was used to determine malondialdehyde (MDA) and glutathione (GSH) levels and heavy metal level in brain. Results showed that there were no significant change in cognitive function, motor coordination, MDA and GSH levels as compared to normal control group at all doses of Calcury tablet, Energic-31 capsule and Basant Kusumakar Rasa. However, heavy metals level in rat’s brain was higher as compared to normal control group at all doses of Calcury tablet, Energic-31 capsule and BKR. In conclusion, Calcury tablet, Energic-31 capsule and BKR in doses equivalent to the human dose does not have appreciable adverse effects on brain which demonstrates the non-toxic nature of metal based Ayurvedic formulations.

Key words: Ayurvedic formulations, neurobehavioral activity, oxidative stress, heavy metals

Introduction

In India, it has been estimated that about 14% sick persons utilizes Indian system of medicine. On the basis of preference, 18.7% population uses Ayurveda for normal ailments, 7.1% in case of sickness and 5% in case of serious ailments.[1] A report by the World Health Organization (WHO) indicates that many people in developing countries still rely on herbal medicine.[2] Majority of people believe that herbal medicines are safe and nontoxic, unlike modern chemotherapeutic agents. Individuals generally use herbal medicine for prolonged periods to achieve a desirable effect. On contrarily, it has been reported that herbal drugs used in the Indian subcontinent and China contain higher concentration of heavy metals than in other areas.[3-5] Another study showed that one of five Ayurvedic herbal medical products, produced in South Asia contains high levels of lead, mercury, and arsenic.[6,7] However, heavy metals are integral to some formulations and are been used for centuries.[8] Ayurvedic formulations are produced after different processes like detoxification, trituration and heating etc., of raw material. Therefore, elements present in finished products do not produce toxicity. Ayurvedic textbooks takes note of the toxicity of heavy metals and recommend special pharmacological process to detoxify them. Those metals which are obtained from ores may contain several impurities. These impurities are removed by Shodhana process. The Shodhana process removes unwanted part from the raw material and separate out impurities. In context of Bhasma, Shodhana means purifying and making the product suitable for the next step i.e. Marana. Ayurveda classifies Shodhana into (a) general process and (b) specific process. In general process for Shodhana, the sheets of metals are heated till red hot and are successively dipped into liquids like oil, buttermilk, cow’s urine etc., and the procedure is repeated 7 times. In specific process
for Shodhana, for some metals a specific process is described for Shodhana e.g., for purification of Jasada, the molten mass is poured in cow's milk for 21 times. Ayurvedic text books emphasize the role of heavy metals in the proper function of the human body. In Rasa Shastra, the metals and the minerals are also termed as "Dhatus" and "Updhatus" because of their specific role in biological systems i.e., they can sustain body tissues by supplementing some of the essential elements to the tissues, whose deficiency causes many undesired problems or disease in the body. The available Ayurvedic literature emphasizes the need of metals in maintaining the metabolic equilibrium of the human body. These metals are mercury, gold, silver, copper, iron, tin, lead, zinc etc. Any deficiency, excess or imbalance in the composition of these metals leads to certain metabolic and anabolic disorders. Equilibrium state of metals in the human body provides the basis for strong immunity. Therefore, any imbalance in the composition of these metals could cause diseases and equilibrium of these metals is seen as a preconditioning for a normal immune defense and general health. Therefore, heavy metals from outside are deliberately added and processed with herbal plants to form herbo-metallic drugs. Each time before burning, the metallic powders are processed with fresh herb juices to neutralize their toxicity. Some of the metals are burnt up to 100 times to make sure the heaviness or toxic effect of the metal is nullified. Once the "Bhasma" is ready it is tested for toxicity. One of the numerous tests the Bhasma has to pass through is called “Varitar” which means the Bhasma, once ready for internal use, floats on water indicating non-existence of heavy metal in it. The “Bhasma” are then transformed to compound formulas by mixing herbal powders. Special herbal juices are used for processing the compound formula for no more toxic metals but for non-toxic herbo-metallic compounds. Therefore, it is claimed that heavy metals are detoxified with herbal extract and excreted out from the body without any harm to body. Bhasmas are metal preparations which are subjected to physico-chemical processing called Samskaras to purify, detoxify and retain the therapeutic properties. Ayurvedic experts have estimated that 35-40% of the approximately 600 medicines in the Ayurvedic formulacy, intentionally contain at least one metal. On the other hand, there are certain plant species, which has high affinity to absorb certain traces of metals from the soil. There are more than 60 plant species which has a natural tendency to absorb traces of metals from the soil which could be used as a natural ingredient and may be important for therapeutic efficacy. Here, trace metal might be working as an active ingredient in the plant material and the possibility of presence of heavy metals in herbal, herbo-metallic and Bhasma are unavoidable. Hence, the aim of present study was to evaluate the effect of chronic administration of Calcury tablet (herbal), Energetic-31 capsule (herbo-metallic) and Basanta Kusumakara Rasa (BKR) on neurobehavioral activity and oxidative stress in rat.

Materials and Methods

Experimental animals

Male wistar rats weighing 200-250 g were used in the present study. Rats were randomly divided into 14 groups with 6 rats in each group. The rats were obtained from the Central Animal House Facility of All India Institute of Medical Sciences, New Delhi and housed in the departmental animal house. The rats were group housed in polyacrylic cages (58 × 25 × 10 cm) with not more than 4 animals per cage and maintained under standard laboratory conditions with natural dark and light cycle. They were allowed free access to standard dry rat diet (Ashirwad, Punjab, India) and tap water ad-libitum. However, 12 h before the behavioral test, the rats were deprived of food as this is known to enhance their motivation to perform the test.

Permission of institutional animal ethics committee

The protocol of the work mentioning details of the experimental technique, justification of the use of animals, number of animals to be used, type of anesthesia, surgical procedure to be used were reviewed and approved by the Institutional Animal Ethics Committee, All India Institute of Medical Sciences, New Delhi India (497/IAEC/(09)).

Drugs preparation, dose and duration of treatment

Calcury tablet (herbal), Energetic-31 capsule (herbo-metallic) and BKR were purchased from market (New Delhi, India) and suspended in normal saline. Mercury chloride, lead acetate, cadmium chloride, sodium arsenite were purchased from Merck (USA) and dissolved in normal saline. These three Ayurvedic formulations have been selected on the basis of preliminary study in which seventy eight drugs were analyzed for heavy metals content. These Ayurvedic formulations contained heavy metals above permissible limit. Hence, these formulations were considered for toxicological evaluation in rats.

Each tablet of Calcury contains Saxifraga ligulata (150 mg), Saccharum officinarum (75 mg), Boerhaavia diffusa (75 mg), Hazarat Yahud Pishiti (57.5 mg), Yava Kshara (15 mg). Extracts derived from Parmelia perlata (150 mg), Crataeva nurevala (150 mg), Tribulus terrestris (75 mg), Picrorrhiza kurroa (75 mg), Tinospora cordifolia (75 mg) and preservatives used were sodium Methylparaben and Sodium Propylparaben. The drug manufacturer was Charak Pharmaceutical Pvt.(I) Limited (Batch no. CA177H). Weight of each tablet was 625 mg. Human dose indicated on package insert was one tablet twice a day.

Energetic-31 capsule contains Shudha Shilajit (450 mg), Shankha Bhasma (10 mg), Tribhang Bhasma (30 mg), Shudha Kuppeelu (50 mg), Kakuktandtwak Bhasma (20 mg), Muktaashuki Bhasma (10 mg), Swarnamakshik Bhasma (10 mg), Shatavari (20 mg), Koonch ke bee (10 mg), Avasgand (20 mg), Dalcheeni (10 mg), Nagkesar (10 mg), Gokhru (10 mg), Sonth (10 mg), Loh Bhasma (10 mg), Lodh Pathani (10 mg), Chhhoti Ilaichi (10 mg), Jabirli (10 mg), Suranjjan Meetha (10 mg), Bidhara (10 mg), Jaiphal (10 mg), Moosli Safed (10 mg), Samundra Sosh (10 mg), Long (10 mg), Babool ka Gord (10 g), Talamkkhana (10 mg), Chhhoti Papal (10 mg), Kali Mirch (10 mg), Safed Chandan (10 mg), Akarkara (10 mg) and Konkol Mireh (10 mg). Weight of each capsule content was 725 mg. The drug manufacturer was Ayurved Vikas Sansthan (Batch no. 997). Human dose indicated on package insert was one capsule twice a day.

Basanta Kusumakara Rasa (BKR) consists of Prawal Bhasma, Chandrodaya or Ras Sindeo, Moti Pishiti, Abhrak Bhasma, Raupy Bhasma, Suvarna Bhasma, Shatavari, Adulasa Swaras, Ganna, Kamal Ke Phool, Mahuti Ke Phool, Kadali-Kanda, Malati Phool,
Animal dose were calculated from human dose per day according to the method followed by Center for Drug Evaluation and Research, Food and Drug Administration (USA), 2005. Three doses of each drug (Calcury tablet, Energic-31 capsule, BKR) were selected for toxicological study according to Schedule Y of Drugs and Cosmetics Acts, 2005. Three doses were human equivalent Therapeutic Dose (TD), 5 times of human equivalent Therapeutic Dose (5TD) and 10 times of human equivalent Therapeutic Dose (10TD).

Animals dose for Calcury tablets were 130, 650, 1500 mg/kg, for Energic-31 capsule were 150, 750, 1500 mg/kg and for BKR were 26, 130, 260 mg/kg. All the solutions were prepared in such a way that each animal was administered solution less than 1 ml. Solutions for Calcury tablet were 50, 200, 300 mg/ml, for Energic-31 capsule were 50, 200, 400 mg/ml and for BKR were 10, 50, 100 mg/ml. All the drug solutions were administered orally to rats for 28 days. The doses and concentration for mercury chloride, lead acetate, cadmium chloride, sodium arsenite was 10 mg/kg/day and 5 mg/ml were administered orally to rat for 28 days.

Experimental design
On day 1 (Baseline, pre-treatment) and on 29th day (post-treatment) neurobehavioral activity was assessed by elevated plus maze, foot fault apparatus, photoactometer, rota rod and passive avoidance apparatus. Animals were decapitated under anesthesia after neurobehavioral activity test. Brain was removed and washed with ice-cold normal saline and stored at −70°C. Brain tissue was thawed and homogenized with 10 times (w/v) ice cold 0.1M phosphate buffer (pH-7.4). Aliquots of homogenate from rat’s brain were used to determine glutathione (GSH), MDA level and heavy metal concentration.

Behavioral tests
Cognitive impairment was evaluated by using passive avoidance and elevated plus maze. The motor incoordination was tested by using rota rod and photoactometer. Only one animal was tested at a time.

Estimation of biochemical markers of oxidative stress
The oxidative stress markers, malondialdehyde (MDA) and reduced GSH levels were estimated in whole brain tissue of rats. The rats were anaesthetized under chloroform anesthesia to decapitate and the brains were quickly removed, cleaned by rinsing with chilled saline and stored at −70°C. The biochemical analysis was performed within 48 h.

Measurement of lipid peroxidation
Malondialdehyde (indicator of lipid peroxidation) was estimated by - Brain tissues were homogenized with 10 times (w/v) 0.1M sodium phosphate buffer (pH 7.4). The reagents acetic acid 1.5 ml (20%, v/v) pH 3.5, 1.5 ml thiobarbituric acid (0.8%, w/v) and 0.2 ml sodium dodecyl sulfate (8.1%, w/v) were added to 0.1 ml of processed tissue sample. The mixture was then kept in boiling water for 60 min. The mixture was then cooled with tap water and 5 ml of n-butanol: pyridine (15:1, v/v) and 1 ml of distilled water were added to it. Then the mixture was vortexed and centrifuged at 4000 rpm for 10 min. The organic layer was withdrawn and absorbance was measured at 532 nm using a spectrophotometer (specord 2000, Analytik Jena, Germany). The concentration of MDA was determined by the linear standard curve.

Estimation of glutathione
Reduced GSH was measured by - Equal quantity of homogenate was mixed with 10% trichlororacetic acid and centrifuged to separate the proteins. To 0.1 ml of this supernatant, 2 ml of 0.3 M phosphate buffer (pH 8.4), 0.5 ml of 5′-dithiobis (2-nitrobenzoic acid) and 0.4 ml of double distilled water were added. The mixture was vortexed and the absorbance was read at 412 nm within 15 min.

Statistical analysis
All datas are expressed as mean ± SEM. Drugs treated groups were compared to normal control and positive control group using one way ANOVA with posthoc Tukey test. Difference with a P < 0.05 was accepted as statistically significant. All the statistical analyses were performed using software (SPSS, version 15).

Observations and Results

Effect of chronic administration of Ayurvedic formulations on learning and memory in rats
One trial passive avoidance
There was significant decrease in mean retention latencies of mercury, lead, cadmium and arsenic treated group as compared to normal control group (P < 0.001). However, there was no significant change in mean retention latencies of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group (P > 0.05) [Table 1].

Elevated plus maze
There was significant increase in mean retention transfer latencies of mercury, lead, cadmium and arsenic treated group as compared to normal control group (P < 0.001). On contrary, there was no significant change in mean transfer retention latencies of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group (P > 0.05) [Table 1].

Effect of chronic administration of Ayurvedic formulations on locomotor activity in rats
Photoactometer (spontaneous locomotor activity)
There was significant decrease in spontaneous locomotor activity of mercury, lead, cadmium and arsenic treated group as compared to normal control group (P < 0.001). However, there was no significant change in spontaneous locomotors activity of...
Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group \( (P > 0.05) \) [Table 1].

**Rota rod**
There was significant decrease of retention time on rod of mercury, lead, cadmium and arsenic treated group as compared to normal control group \( (P < 0.001) \). However, there was no significant change in retention time on rod of Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group \( (P > 0.05) \) [Table 1].

**Effect of chronic administration of Ayurvedic formulations on oxidative stress in rats**

**Glutathione estimation**
There was significant decrease of GSH level in brain of mercury, lead, cadmium and arsenic treated group as compared to normal control group \( (P < 0.001) \). However, there was no significant change in GSH level in brain of Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group \( (P > 0.05) \) [Figure 1].

**Malondialdehyde estimation**
There was significant increase of MDA level in brain of mercury, lead, cadmium and arsenic treated group as compared to normal control group \( (P < 0.001) \). However, there was no significant change in MDA level in brain of Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group \( (P > 0.05) \) [Figure 1].

**Table 1: Effect of Ayurvedic formulations on learning and memory and locomotor activity**

| Experimental groups | Passive avoidance | Elevated plus maze | Rota rod | Photoactometer (counts/10 min) |
|---------------------|------------------|-------------------|----------|-------------------------------|
|                     | ITL (s)          | RTL (s)           | IL (s)   | RL (s) | IL (s) | RL (s) |
| Normal control      | 44.52±7.57       | 203.33±37.22      | 36.3±11.12 | 10.5±2.3 | 144±19.48 | 156.5±10 |
| Mercury treated     | 40.8±5.42        | 68.46±4.23***     | 25.5±5.62 | 52.5±4.6*** | 127±15.44 | 94±26.8** |
| Cadmium treated     | 36.4±7.39        | 119.53±6.08***    | 26.8±7.74 | 41.2±6.4*** | 144.7±19.11 | 109.5±22.3** |
| Lead treated        | 38.9±6.2         | 93.6±2.23***      | 33.2±4.2 | 44.5±4.9*** | 129.7±7.28 | 101.8±9.8** |
| Arsenic treated     | 27.4±2.57        | 105.02±7.49***    | 28.2±6.38 | 46.0±3.2*** | 137±16.96 | 107±6.4** |
| Calcury (TD)        | 45.95±10.51      | 198.62±13.22      | 29.3±4.9 | 14.3±2.74 | 181±21.27 | 145.3±15.02 |
| Calcury (5TD)       | 43.25±7.34       | 180.1±19.98       | 32.3±5.4 | 17.3±5.45 | 196.17±25.81 | 142.5±19.71 |
| Calcury (10TD)      | 34.12±11.65      | 169.68±21.11      | 33.0±6.4 | 14.6±4.13 | 128±31.19 | 146.83±24.51 |
| Energetic-31 (TD)   | 27.98±3.67       | 185.12±17.57      | 31.8±4.37 | 14.3±8.03 | 110.83±27.74 | 157.17±21.46 |
| Energetic-31 (5TD)  | 38.33±10.61      | 186.5±20.39       | 32.7±2.14 | 16.3±8.64 | 122.83±9.36 | 133.83±14.05 |
| Energetic-31 (10TD) | 27.6±7.47        | 177.53±14.5      | 34.6±6.34 | 18.6±5.48 | 125.5±15.33 | 140±15.82 |
| BKR (TD)            | 35.42±7.4        | 195.83±23.74      | 37.8±7.32 | 15.3±3.15 | 118.67±18.49 | 132.67±12.23 |
| BKR (5TD)           | 42.17±9.32       | 166.57±31.7       | 32.8±8.37 | 15.17±6.24 | 165±9.28 | 168.3±12.45 |
| BKR (10TD)          | 31.53±3.64       | 185.8±24.9        | 32.1±5.1 | 18.3±5.4 | 140.83±13.13 | 118.17±15.21 |

IL: Initial latency, RL: Retention latency, *\( P<0.05 \); **\( P<0.01 \); ***\( P<0.001 \); As compared to normal control, ITL: Initial transfer latency, RTL: Retention transfer latency, TD: Therapeutic dose, BKR: Basanta Kusumakara Rasa
of mercury treated groups (203.70 ± 5.15 µg/g) as compared to normal control group (2.01 ± 0.18 µg/g) (P < 0.001). However, there was also significant increase of mean mercury concentration level in brain with increasing doses of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group (P < 0.001) but on contrary, the mercury in brain of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group was significantly less as compared to mercury treated group (P < 0.001) [Table 2].

**Cadmium estimation**

There was significant increase of cadmium concentration in brain of cadmium treated groups (289.19 ± 5.35 µg/g) as compared to normal control group (0.44 ± 0.08 µg/g) (P < 0.001). However, there was also significant increase of mean cadmium concentration in brain with increasing doses of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group (P < 0.001) but on contrary, the cadmium in brain of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group was significantly less as compared to cadmium treated group [Table 2].

**Arsenic estimation**

There was significant increase of arsenic concentration in brain of arsenic treated groups (88.4 ± 4.9 µg/g) as compared to normal control group (0.25 ± 0.05 µg/g) (P < 0.001). However, there was also significant increase of mean arsenic concentration in brain with increasing doses of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and Kusumkara (TD, 5TD, 10TD) treated group as compared to normal control group (P < 0.001) but on contrary, the arsenic in brain of Calcury (TD, 5TD, 10TD), Energic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group was significantly less as compared to arsenic treated group [Table 2].

### Table 2: Effect of Ayurvedic formulations on brain heavy metal levels

| Experimental group                        | Mercury (µg/g) | Lead (µg/g) | Cadmium (µg/g) | Arsenic (µg/g) |
|-------------------------------------------|----------------|-------------|----------------|---------------|
| Normal control                            | 2.01±0.18      | 1.6±1.5     | 0.44±0.08      | 0.25±0.05     |
| Mercury treated                           | 203.70±5.15*** | 4.02±0.6    | 0.59±0.05      | 0.33±0.02     |
| Cadmium treated                           | 3.59±0.25      | 3.67±0.4    | 289.19±5.35*** | 0.19±0.03     |
| Lead treated                              | 3.04±0.38      | 421.9±6.5***| 0.52±0.18      | 0.32±0.08     |
| Arsenic treated                           | 3.61±0.1      | 3.7±3.7     | 0.61±0.9       | 88.4±4.9***   |
| Calcury (TD)                              | 6.08±1.31      | 4.9±1.4     | 0.48±0.06      | 0.38±0.16     |
| Calcury (5TD)                             | 6.80±1.1       | 5.1±1.7     | 0.58±0.11      | 0.42±0.12     |
| Calcury (10TD)                            | 7.61±1.14      | 5.9±0.3     | 0.61±0.14      | 0.46±0.04     |
| Energic-31 (TD)                           | 12.14±1.26     | 17.6±3.5    | 0.81±0.16      | 0.34±0.11     |
| Energic-31 (5TD)                          | 12.31±1.35     | 23.9±2.5    | 0.84±0.15      | 0.37±0.05     |
| Energic-31 (10TD)                         | 14.38±2.08     | 28.8±3.1    | 0.88±0.28      | 0.38±0.08     |
| BKR (TD)                                  | 24.79±1.80     | 8.7±3.4     | 0.69±0.10      | 0.29±0.11     |
| BKR (5TD)                                 | 27.04±1.30     | 9.7±3.6     | 0.74±0.22      | 0.34±0.07     |
| BKR (10TD)                                | 31.29±1.09     | 9.8±2.5     | 0.89±0.27      | 0.36±0.05     |

***P<0.001; *As compared to normal control; BKR: Basanta Kusumakara Ras; TD: Therapeutic dose

**Discussion**

Ayurveda is a widely practiced system in India and the used formulations are herbal, herbo-metallic and Bhasma. Ayurvedic text books emphasize the role of metals in proper functioning of the human body. Therefore, metals are inevitable part deliberately added and processed with herbal plants to form herbo-metallic drugs. Ayurvedic experts have estimated that 35-40% of the approximately 600 medicines in the Ayurvedic formulary intentionally contain at least one metal. [33] Bhasma contains only metals which are detoxified during processing (Shodhana). So possibility of presence of heavy metals in herbo-metallic and Bhasma are unavoidable. Therefore, objective of our study was the determination of effect of chronic administration of Ayurvedic formulations on neurobehavioral activity and oxidative stress in rats.

The case reports suggests that lead content is a bigger problem with Indian HMPs and poisoning due to heavy metals have been regularly reported in the last three decades. The mercury poisoning occurs by deposition in human cortical neuron and in a scattered group of neurons in the brain stem and cerebellum by generation of free radicals, release of intracellular calcium, lysosomal enzyme or cytoskeleton disorganization. Neurological deficits due to organic mercury exposure includes encephalopathy with persistent neurological disabilities while inorganic mercury exposure produce polyneuropathy and tremor and further results decrease in visual acuity, ataxic gait and involuntary jerk movements. Most of the cognitive and emotional problems have been found in patients exposed to inorganic or organic mercury. [10]
On contrary, our study shows that the animals treated with Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) containing heavy metals does not cause cognition impairment and motor incoordination while positive control group in which mercury, lead, cadmium and arsenic salts were given orally to rats for 28 days caused cognition impairment and motor incoordination. The oxidative stress markers like MDA and GSH level has not been altered as compared to normal control group while there was significant decrease in GSH level and increase in MDA level in brain of positive control in which mercury, lead, cadmium and arsenic salts were given orally to rats for 28 days. We observed the higher level of heavy metal concentration in rat’s brain of positive control, Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group as compared to normal control group. However, mercury, lead, cadmium and arsenic level in brain of Calcury (TD, 5TD, 10TD), Energetic-31 (TD, 5TD, 10TD) and BKR (TD, 5TD, 10TD) treated group were significantly very less as compared to positive control in which mercury, lead, cadmium and arsenic salts treated group. However, no sign and symptoms, toxic manifestations were observed in these groups. Possibility of raised heavy metals level in brain could be[1] low heavy metals level exposure to rats[2] heavy metal levels were estimated immediately after 28 days administration of drugs[3] heavy metals has longer half life and[4] elimination from the body is slow. Hence, rats treated with Ayurvedic formulations showed raised heavy metal levels in brain.

The results of present study showed that herbo-metallic formulation and Bhasma are non-toxic even though these drugs contain metals. The reason for nontoxic nature of herbo-metallic formulation and Bhasma in animal could be,[1] metals in Ayurvedic formulation are not present in elemental form,[2] Physico-chemical state of the heavy metals in the form of Ayurvedic medicine is totally different from the known Physico-chemical forms of that metal.[12,13,28,31]

Heavy metal preparations (Bhasma) have been used in Indian System of Medicine for centuries with claimed efficacy and safety. Processed mercury shows excellent therapeutic activities in low doses without producing toxic effect in the human subjects. The toxic effects are due to impure mercury or improper use of processed mercury. The complication and toxic effects of metals has already been mentioned in Ayurveda.[8,31] However, Ayurvedic literature also mentions that metals are subjected to Samskaras which attributes to purification, detoxification and restoration of its therapeutic properties.[12]

**Conclusion**

The results of present study are coherent with the Ayurvedic literature. There were no significant changes in cognitive and motor functions and biochemical parameters of Calcury, Energetic-31 and Basanta Kasumkara Rasa treated rats, demonstrates the safety of Ayurvedic formulations. These drugs are clinically used by a large number of populations without showing heavy metals toxicity. Hence, Calcury, Energetic-31 and Basanta Kasumkara Rasa can be used at recommended dose and duration.

**References**

1. Singh P, Yadav R, Pandey A. Utilization of indigenous systems of medicine and homoeopathy in India. Indian J Med Res 2005;122:137-42.
2. Eisenberg DM, Davis RB, Ettrner SL, Appel S, Wilksey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998;280:1569-75.
3. Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003;52:1361-71.
4. Chan TY, Chan JC, Tomlinson B, Critchley JA. Poisoning by Chinese herbal medicines in Hong Kong: A hospital-based study. Vet Hum Toxicol 1994;36:546-7.
5. Dunabin DW, Tallis GA, Popplewell PY, Lee RA. Lead poisoning from Indian herbal medicine (Ayurveda). Med J Aust 1992;157:835-6.
6. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004;292:2868-73.
7. Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, et al. Lead, mercury, and arsenic in US-and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 2008;300:915-23.
8. Thatte UM, Rege NN, Phatak SD, Danaharuk SA. The flip side of Ayurveda. J Postgrad Med 1993;39:179-82.
9. Vaiday, Doile, Bhasma. 1996. Available from: http://www.en.wikipedia.org/wiki/Bhasma. [Last cited 2012 Mar 15].
10. Prakash VB. The therapeutic use of metals based on rasayan shastra of Ayurveda for the treatment of cancer. Australia: Presentation at First World Cancer Congress of Independent Medical Research Sydney; 1994. Available from: en.wikipedia.org/wiki/Rasayan. [Last cited 2012 Mar 15].
11. Prpić-Majić D, Pizent A, Jurasović J, Pongracić J, Restek-Samarzija N. Lead poisoning associated with the use of Ayurvedic metal-mineral tonics. J Toxicol Clin Toxicol 1996;34:417-23.
12. Chauhan P. Ayurvedic metallic medicines are not fatal. 2012. Available from: http://www.ayurveda-foryou.com/heavy_metals/heavy_metals3.html. [Last cited 2012 Feb 11].
13. Gogtay N, Bhatt HA, Dalvi SS, Krishsagar NA. Use and safety of non-allopathic Indian medicines. Drug Saf 2002;25:1005-19.
14. Kohli KR. Ayurveda heritage. Association of manufacturers of Ayurvedic medicines. Sahibabad, Uttar Pradesh; 2005. p. 1:1-16. Available from: http://www.mail-archive.com/goanet@lists.goanet.org/msg46705.html. [Last cited 2011 Dec 5].
15. Ayurvedic Formulary of India. Part I and II. 2nd revised English ed. New Delhi: Ministry of Health and Family Welfare, Govt. of India; 2005. p. 273.
16. Guidance for industry nonclinical studies for the safety evaluation of pharmaceutical excipients. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Pharmacology/Toxiology; 2005. Available from: http://www.fda.gov/cder/guidance/index.htm [Last cited 2012 March 15].
17. Schedule Y. Drugs and cosmetics (2nd amendment) rules. 2005. Ministry of Health and Family Welfare (Department of health). Requirements and guidelines for permission to import and/or manufacture of new drugs for sale or to undertake clinical trials. Available from: http://www.dbtbiosafety.nic.in/acct/Schedule_Ypdf [Last cited 2012 February 10].
18. ATSDR 1999a. Toxicological profile for mercury, lead, cadmium, arsenic. 1999. Available from: http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=115 and tid=24 [Last cited 2012 March 15].
19. Gupta YK, Veerendra Kumar MH, Srivastava AK. Effect of Centella asiatica on pentyleneetetrazole-induced kindling, cognition and oxidative stress in rats. Pharmacol Biochem Behav 2003;74:579-85.
20. Gupta YK, Brijal S, Sharma U, Jagannathan NR, Gulati A. Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats. Life Sci 2005;77:15-27.
21. Ohikawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
22. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
23. Jacobs MB, Yamaguchi S, Goldwater LJ, Gilbert H. Determination of mercury in blood. Am Ind Hyg Assoc J 1960;21:475-80.
24. Kumar G, Srivastava A, Sharma SK, Gupta YK. Safety evaluation of an Ayurvedic medicine, Arogyavardhini vati on brain, liver and kidney in rats. J Ethnopharmacol 2012;140:151-60.
25. Chopra A, Doiphode V. Ayurvedic medicine. Core concept, therapeutic principles, and current relevance. Med Clin North Am 2002;86:75-89.
26. Ernst E, White A. The BBC survey of complementary medicine use in the UK. Complement Ther Med 2000;8:32-6.
27. Lynch E, Braithwaite R. A review of the clinical and toxicological aspects of 'traditional' (herbal) medicines adulterated with heavy metals. Expert Opin Drug Saf 2005;4:769-78.
28. Garnier R, Poupon J. Lead poisoning from traditional Indian medicines. Presse Med 2006;35:1177-80.
29. Castoldi AF, Coccini T, Ceccatelli S, Manzo L. Neurotoxicity and molecular effects of methylmercury. Brain Res Bull 2001;55:197-203.
30. Garza A, Vega R, Soto E. Cellular mechanisms of lead neurotoxicity. Med Sci Monit 2006;12:RA57-65.
31. Dash VB. Alchemy and Metallic Medicines in Ayurveda. New Delhi: Concept Publications; 1986. p. 1-5 and 48-92.
32. Nishteswar K, Vidyanath R. Ayurvediya Rasashastra. Varanasi, India: Chaukhamba surbharati Prakashan; 2005. p. 84.